/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The Bio Report
  2. Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer
Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer

The Bio Report · Oct 21, 2026

BriaCell’s off-the-shelf cell therapy takes multi-antigen aim at metastatic breast cancer, with HLA matching and a Phase 3 readout ahead.

Whole-cell vaccines hit diverse tumor clones through two immune arms

Bill Williams says Bria-IMT presents many cancer-associated antigens, not just one, so it can activate adaptive T cells against multiple mutated tumor clones. He adds the cell-based approach also engages the innate immune system, which can recognize tumors undergoing immune evasion, further limiting cancer's ability to escape.

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer thumbnail

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer

The Bio Report·a month ago

BriaCell's phase 3 can fall back to 30% mortality cut

Bill Williams says BriaCell's phase 3 seeks a 40% reduction in mortality. If it misses that, the company can continue and aim for a 30% reduction; FDA agreed either result would support full approval for the therapy, so no separate confirmatory study would be needed.

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer thumbnail

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer

The Bio Report·a month ago

Four cell lines can HLA-match over 99% of patients

Bill Williams says BriaCell's engineered OTS cell lines express 15 HLA molecules across four lines. That lets them single-match over 99% of the population and double-match over 90%, making a personalized off-the-shelf therapy practical after only a one-week saliva test rather than complex tumor sequencing.

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer thumbnail

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer

The Bio Report·a month ago

Cell therapy can work after 13 failed breast cancer treatments

Bill Williams describes a patient who had failed 13 prior therapy attempts and then had universal tumor regression on Bria-IMT plus a checkpoint inhibitor. Another with brain metastasis stayed on therapy for two years, challenging the idea that cancer vaccines only work in healthier, earlier-stage patients.

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer thumbnail

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer

The Bio Report·a month ago

Bria-OTS Plus engineers co-stimulation for repeated cancer killing

Bill Williams says BriaCell further modified its OTS cells to express co-stimulatory molecules and cytokines. In lab studies, these OTS Plus cells activated naive T cells and killed cancer cells on repeated challenges, suggesting stronger and more durable immune activation than just HLA matching alone.

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer thumbnail

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer

The Bio Report·a month ago

Checkpoint inhibitors reduce Bria-IMT's need for HLA matching

Bill Williams says HLA matching was not as critical for Bria-IMT when combined with an immune checkpoint inhibitor, so BriaCell is not matching patients for that product. The company is instead building HLA matching into its next-generation Bria-OTS and OTS Plus pipelines as those programs advance.

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer thumbnail

Developing an Off the Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer

The Bio Report·a month ago